

Application No. 10/528,612
Amendment Dated 12 January 2007
Reply to Office Action of 15 December 2006

Remarks/Arguments:

Applicants are filing herein an amended set of claims in response to the restriction requirement dated 15 December 2006.

Applicants hereby elect Group I "Claims 1-3, 12, drawn to the process for the preparation of a compound of Formula (I), classified in class 548, subclass 453, for example", without traverse.

The Examiner additionally requires the election of a single compound including an exact definition of all substituents and variables. Applicants elect the compound(s) wherein:

- R⁴ and R⁵ are chloro;
- R⁶ is methyl; and
- R⁷ is -C(=O)CH₃.

Applicants have amended the claims accordingly to expedite prosecution. Applicants further corrected two typographical errors replacing "method" for "process".

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100837-1P US.

Respectfully submitted,
/Lucy Padget/

Name: Lucy Padget
Dated: 12 January 2007
Reg. No.: L0074
Phone No.: 781-839-4182
Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451